BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37086333)

  • 1. Negative predictive value of PSMA PET scan for lymph node staging in patients undergoing robotic radical prostatectomy and pelvic lymph node dissection.
    Adiyat KT; Pooleri GK; Cherian DT; Santhamma SGN; Ravichandran K; Sundaram S
    Int Urol Nephrol; 2023 Jun; 55(6):1453-1457. PubMed ID: 37086333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
    Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary lymph-node staging with
    Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
    Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.
    Maestroni UV; Campobasso D; Guarino G; Acampora A; Scarlattei M; Ziglioli F; Dinale F; Baldari G; Migliari S; Gasparro D; Ferretti S; Silini EM; Ruffini L
    Chin Clin Oncol; 2023 Jun; 12(3):22. PubMed ID: 37417288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gallium-68-prostate-specific membrane antigen (
    van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
    BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.
    Hope TA; Eiber M; Armstrong WR; Juarez R; Murthy V; Lawhn-Heath C; Behr SC; Zhang L; Barbato F; Ceci F; Farolfi A; Schwarzenböck SM; Unterrainer M; Zacho HD; Nguyen HG; Cooperberg MR; Carroll PR; Reiter RE; Holden S; Herrmann K; Zhu S; Fendler WP; Czernin J; Calais J
    JAMA Oncol; 2021 Nov; 7(11):1635-1642. PubMed ID: 34529005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How accurate is
    Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with
    Yaxley JW; Raveenthiran S; Nouhaud FX; Samartunga H; Yaxley AJ; Coughlin G; Delahunt B; Egevad L; McEwan L; Wong D
    J Urol; 2019 Apr; 201(4):815-820. PubMed ID: 30672842
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Esen T; Falay O; Tarim K; Armutlu A; Koseoglu E; Kilic M; Seymen H; Sarikaya AF; Kiremit MC; Balbay MD; Canda AE; Baydar DE; Kordan Y; Demirkol MO; Tilki D
    Eur Urol Focus; 2021 Mar; 7(2):288-293. PubMed ID: 33509671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.
    Stabile A; Pellegrino A; Mazzone E; Cannoletta D; de Angelis M; Barletta F; Scuderi S; Cucchiara V; Gandaglia G; Raggi D; Necchi A; Karakiewicz P; Montorsi F; Briganti A
    Eur Urol Oncol; 2022 Feb; 5(1):1-17. PubMed ID: 34538770
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
    Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of
    Zhang Q; Zang S; Zhang C; Fu Y; Lv X; Zhang Q; Deng Y; Zhang C; Luo R; Zhao X; Wang W; Wang F; Guo H
    J Transl Med; 2017 Nov; 15(1):230. PubMed ID: 29115970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management.
    Haxhimolla J; Kua B; Gilbourd D; Haxhimolla H
    Semin Oncol Nurs; 2020 Aug; 36(4):151044. PubMed ID: 32723519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational use of Ga-68 PSMA PET-CT according to nomograms and risk groups for the detection of lymph node metastasis in prostate cancer.
    Madendere S; Kılıç M; Köseoğlu E; Aykanat İC; Eden AB; Coşkun B; Tekkalan FB; Balbay MD
    Urol Oncol; 2024 Feb; 42(2):29.e9-29.e15. PubMed ID: 38114351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
    BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Kopp J; Kopp D; Bernhardt E; Manka L; Beck A; Gerullis H; Karakiewicz P; Schoerner W; Hammerer P; Schiffmann J
    World J Urol; 2020 Dec; 38(12):3085-3090. PubMed ID: 32103332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
    Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
    BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study assessing the accuracy of [18F]-fluorocholine PET/CT for primary staging of lymph node metastases in intermediate and high-risk prostate cancer patients undergoing robotic-assisted laparoscopic prostatectomy with extended lymph node dissection.
    Puterman C; Bjöersdorff M; Amidi J; Anand A; Soller W; Jiborn T; Kjölhede H; Trägårdh E; Bjartell A
    Scand J Urol; 2021 Aug; 55(4):293-297. PubMed ID: 33939583
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Yılmaz B; Şahin S; Ergül N; Çolakoğlu Y; Baytekin HF; Sökmen D; Tuğcu V; Taşçı Aİ; Çermik TF
    Ann Nucl Med; 2022 Jul; 36(7):597-609. PubMed ID: 35426599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection.
    Dekalo S; Kuten J; Mintz I; Fahoum I; Gitstein G; Keizman D; Sarid D; Matzkin H; Mabjeesh NJ; Beri A; Even-Sapir E; Yossepowitch O; Mano R
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):910-916. PubMed ID: 33790418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.